Briefing Summary: US FDA Posts Advisory Committee Materials For Sprout Pharmaceuticals’ Flibanserin For Hypoactive Sexual Desire Disorder – JUN 4, 2015 (BRUDAC-DSRM)
The US FDA has posted details, including company and FDA Briefing Materials, for the Thursday, June 4, 2015 Joint Meeting of the Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSRM). The Committees will discuss the safety and efficacy of flibanserin (100 mg tablets) by Sprout Pharmaceuticals Inc. (Sprout) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.